Edwards Lifesciences (EW) CEO awarded stock, options and makes share gifts
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Edwards Lifesciences CEO Bernard J. Zovighian reported multiple equity compensation and routine share transfers. On May 7, 2026, he received 43,800 restricted stock units and 43,800 performance-based stock units under the company’s Long-Term Stock Incentive Compensation Program, plus options for 245,300 shares of common stock at an exercise price of $82.76 per share.
The time-based restricted stock units are scheduled to vest in four equal annual installments starting one year after grant, while the performance units are scheduled to vest on May 7, 2029 based on three-year performance goals. On the same date, options are scheduled to vest in 36 approximately equal monthly installments beginning one month after grant.
He also reported bona fide gifts totaling 19,422 shares and tax-withholding dispositions totaling 9,551 shares between May 7–11, 2026. After these transactions, he holds 104,795.6499 shares directly, 21,750.5511 shares indirectly through a trust, and 3,733.5603 shares indirectly via a 401(k) plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
19,422 shares gifted
Mixed
10 txns
Insider
Zovighian Bernard J
Role
CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Gift | Common Stock | 5,489 | $0.00 | -- |
| Gift | Common Stock | 5,489 | $0.00 | -- |
| Gift | Common Stock | 4,222 | $0.00 | -- |
| Tax Withholding | Common Stock | 5,398 | $82.76 | $447K |
| Gift | Common Stock | 4,222 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Acquire) | 245,300 | $0.00 | -- |
| Grant/Award | Performance Rights | 43,800 | $0.00 | -- |
| Grant/Award | Common Stock | 43,800 | $0.00 | -- |
| Tax Withholding | Common Stock | 4,153 | $83.20 | $346K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 104,795.65 shares (Direct, null);
Common Stock — 21,750.551 shares (Indirect, By Trust);
Employee Stock Option (Right to Acquire) — 245,300 shares (Direct, null);
Performance Rights — 43,800 shares (Direct, null)
Footnotes (1)
- These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.
Key Figures
Restricted stock unit grant: 43,800 shares
Performance unit grant: 43,800 shares
Option grant size: 245,300 shares
+5 more
8 metrics
Restricted stock unit grant
43,800 shares
Time-based RSUs granted May 7, 2026
Performance unit grant
43,800 shares
Performance rights scheduled to vest May 7, 2029
Option grant size
245,300 shares
Employee stock options granted May 7, 2026
Option exercise price
$82.76/share
Conversion or exercise price for new options
Gifted shares
19,422 shares
Total bona fide gifts reported in filing
Tax-withholding shares
9,551 shares
Shares delivered for tax liabilities
Direct holdings after
104,795.6499 shares
Direct common stock after transactions
Trust holdings after
21,750.5511 shares
Indirect common stock via trust after transactions
Key Terms
restricted stock units, Performance Rights, Employee Stock Option (Right to Acquire), bona fide gift, +2 more
6 terms
restricted stock units financial
"These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Rights financial
""Performance Rights", "transaction_shares": "43800.0000""
Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.
Employee Stock Option (Right to Acquire) financial
""Employee Stock Option (Right to Acquire)", "transaction_shares": "245300.0000""
bona fide gift financial
""transaction_code_description": "Bona fide gift""
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
Long-Term Stock Incentive Compensation Program financial
"granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program"
tax liability by delivering securities financial
""transaction_code_description": "Payment of exercise price or tax liability by delivering securities""
FAQ
What equity awards did Edwards Lifesciences (EW) grant to CEO Bernard Zovighian?
Edwards Lifesciences granted CEO Bernard Zovighian 43,800 restricted stock units, 43,800 performance-based stock units, and options on 245,300 shares at an exercise price of $82.76. These awards were issued under the Long-Term Stock Incentive Compensation Program on May 7, 2026.
How and when will Bernard Zovighian’s new Edwards (EW) stock awards vest?
The time-based restricted stock units vest in four equal annual installments starting one year after May 7, 2026. The performance-based units are scheduled to vest on May 7, 2029, depending on three-year performance goals, while the options vest in 36 monthly installments beginning one month after grant.
What do the bona fide gifts reported by Edwards (EW) CEO Bernard Zovighian represent?
The filing lists four bona fide gift transfers totaling 19,422 Edwards Lifesciences shares. These gifts, coded “G,” indicate transfers made without consideration, commonly used for charitable or personal estate planning, and do not represent open-market sales of stock.
What are the terms of Bernard Zovighian’s new Edwards (EW) stock options?
Bernard Zovighian received options on 245,300 Edwards Lifesciences shares with a conversion or exercise price of $82.76 per share. These options begin vesting one month after May 7, 2026, in approximately 36 equal monthly installments and expire on May 6, 2033.